ConductScience.org, home

Paper32738245

Granzyme B Inhibition by Tofacitinib Blocks the Pathology Induced by CD8 T Cells in Cutaneous Leishmaniasis.

Novais FO and 2 others. J Invest Dermatol, 2021. Cited by 37 papers, by iCite.

Cite this record

ConductScience Library. Granzyme B Inhibition by Tofacitinib Blocks the Pathology Induced by CD8 T Cells in Cutaneous Leishmaniasis. Papers, record 32738245. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32738245

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Granzyme B Inhibition by Tofacitinib Blocks the Pathology Induced by CD8 T Cells in Cutaneous Leishmaniasis.
PubMed
Journal
J Invest Dermatol
PubMed
Year
2021
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
37
iCite
Relative citation ratio, by iCite
2.26
iCite
Revised in PubMed
2021-10-08
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Novais FOFernanda O
2Nguyen BTBa T
3Scott PPhillip

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antiparasitic AgentsMajor topic
GranzymesMajor topic
Leishmaniasis, CutaneousMajor topic
PiperidinesMajor topic
PyrimidinesMajor topic
T-Lymphocytes, CytotoxicMajor topic
Adoptive Transfer
Animals
Biopsy
Disease Models, Animal
Drug Therapy, Combination
Humans
Leishmania braziliensis
Mice
Parasite Load
Severity of Illness Index
Skin
Th1 Cells

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
R01 AI150606NIAID NIH HHSUnited StatesR01AI150606PubMed and NIH

Source NIH RePORTER

Download CSV of grants

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in33618802Identifying a Potential Therapeutic Host Target in Cutaneous Leishmaniasis.https://conductscience.org/library/papers/33618802

Source PubMed

Download CSV of comments and corrections

References73

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128169015Janus kinase inhibitors in dermatology: A systematic review.J Am Acad Dermatol2017https://conductscience.org/library/papers/28169015PubMed
225036052Genomic profiling of human Leishmania braziliensis lesions identifies transcriptional modules associated with cutaneous immunopathology.J Invest Dermatol2015https://conductscience.org/library/papers/25036052PubMed
38929454Interleukin-15 induces the expression of mRNAs of cytolytic mediators and augments cytotoxic activities in primary murine lymphocytes.Cell Immunol1996https://conductscience.org/library/papers/8929454PubMed
412032913Failure of early treatment of cutaneous leishmaniasis in preventing the development of an ulcer.Clin Infect Dis2002https://conductscience.org/library/papers/12032913PubMed
530630365Tuberculosis, hepatitis B and herpes zoster in tofacitinib-treated patients with rheumatoid arthritis.Immunotherapy2019https://conductscience.org/library/papers/30630365PubMed
628004029Idiopathic erythema multiforme: Evidence of underlying Janus kinase-signal transducer and activator of transcription activation and successful treatment with tofacitinib.JAAD Case Rep2016https://conductscience.org/library/papers/28004029PubMed
727842401Reversal of Alopecia Universalis by Tofacitinib: A Case Report.Ann Intern Med2016https://conductscience.org/library/papers/27842401PubMed
831925782Compartmentalized cytotoxic immune response leads to distinct pathogenic roles of natural killer and senescent CD8+ T cells in human cutaneous leishmaniasis.Immunology2020https://conductscience.org/library/papers/31925782PubMed
919242513Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients.J Invest Dermatol2009https://conductscience.org/library/papers/19242513PubMed
1031106368Tofacitinib modulates the VZV-specific CD4+ T cell immune response in vitro in lymphocytes of patients with rheumatoid arthritis.Rheumatology (Oxford)2019https://conductscience.org/library/papers/31106368PubMed
1130038217Cytotoxic CD8+ T cells recognize and kill Plasmodium vivax-infected reticulocytes.Nat Med2018https://conductscience.org/library/papers/30038217PubMed
1226290604Lymphocytic Choriomeningitis Virus Expands a Population of NKG2D+CD8+ T Cells That Exacerbates Disease in Mice Coinfected with Leishmania major.J Immunol2015https://conductscience.org/library/papers/26290604PubMed
1322873531Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.N Engl J Med2012https://conductscience.org/library/papers/22873531PubMed
1417188506Induction of granzyme B and T cell cytotoxic capacity by IL-2 or IL-15 without antigens: multiclonal responses that are extremely lytic if triggered and short-lived after cytokine withdrawal.Cytokine2006https://conductscience.org/library/papers/17188506PubMed
1519346378Association of treatment of American cutaneous leishmaniasis prior to ulcer development with high rate of failure in northeastern Brazil.Am J Trop Med Hyg2009https://conductscience.org/library/papers/19346378PubMed
1622873530Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.N Engl J Med2012https://conductscience.org/library/papers/22873530PubMed
1725129481Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.Nat Med2014https://conductscience.org/library/papers/25129481PubMed
1828214226CD49a Expression Defines Tissue-Resident CD8+ T Cells Poised for Cytotoxic Function in Human Skin.Immunity2017https://conductscience.org/library/papers/28214226PubMed
1927516546Network pharmacology of JAK inhibitors.Proc Natl Acad Sci U S A2016https://conductscience.org/library/papers/27516546PubMed
209708802Coxsackievirus B3-induced myocarditis: perforin exacerbates disease, but plays no detectable role in virus clearance.Am J Pathol1998https://conductscience.org/library/papers/9708802PubMed

See all 73 referencesDownload CSV of references

Cited by25

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 37 citations.

PMIDTitleJournalYearIn PapersSource
42084739JAK/STAT inhibition reprograms T cell activation and metabolism in inflammatory arthritis patients.Inflamm Res2026https://conductscience.org/library/papers/42084739PubMed
42020513Lymphocyte-mediated immune responses to Leishmania infection.Nat Rev Immunol2026https://conductscience.org/library/papers/42020513PubMed
41272797Immunomodulatory and regenerative effects of human umbilical cord MSC-EVs in Cutaneous Leishmaniasis.Stem Cell Res Ther2025https://conductscience.org/library/papers/41272797PubMed
40982482Topical AuNPs-Cys-Sm29 gel modulates the course of lesion development in experimental cutaneous leishmaniasis.PLoS Negl Trop Dis2025https://conductscience.org/library/papers/40982482PubMed
40952132Step-by-step: the CD8 T cell journey in leishmaniasis.mBio2025https://conductscience.org/library/papers/40952132PubMed
40512023Oxygen and immunity to Leishmania infection.Infect Immun2025https://conductscience.org/library/papers/40512023PubMed
40373956Hypoxia and IL-15 Cooperate to Induce Perforin Expression by CD8 T Cells and Promote Damage to the Skin in Murine Cutaneous Leishmaniasis.J Invest Dermatol2025https://conductscience.org/library/papers/40373956PubMed
40287829An overview of host immune responses against Leishmania spp. infections.Hum Mol Genet2025https://conductscience.org/library/papers/40287829PubMed
39587036Chemokines Signature and T Cell Dynamics in Leishmaniasis: Molecular insight and therapeutic application.Expert Rev Mol Med2024https://conductscience.org/library/papers/39587036PubMed
39460345Immunotherapeutic Strategies as Potential Treatment Options for Cutaneous Leishmaniasis.Vaccines (Basel)2024https://conductscience.org/library/papers/39460345PubMed
39432677CD8 cell-derived granzyme B may be a predictor for coronary artery involvement and MACE in Takayasu arteritis patients.Clin Exp Immunol2025https://conductscience.org/library/papers/39432677PubMed
39428748Senescence-related genes are associated with the immunopathology signature of American tegumentary leishmaniasis lesions and may predict progression to mucosal leishmaniasis.Clin Exp Immunol2025https://conductscience.org/library/papers/39428748PubMed
38882602CXCR6+CD69+ CD8+ T cells in ascites are associated with disease severity in patients with cirrhosis.JHEP Rep2024https://conductscience.org/library/papers/38882602PubMed
38787268Improved Treatment Outcome Following the Use of a Wound Dressings in Cutaneous Leishmaniasis Lesions.Pathogens2024https://conductscience.org/library/papers/38787268PubMed
38709823CCR5 promotes the migration of pathological CD8+ T cells to the leishmanial lesions.PLoS Pathog2024https://conductscience.org/library/papers/38709823PubMed
37873253CCR5 promotes the migration of CD8+ T cells to the leishmanial lesions.bioRxiv2023https://conductscience.org/library/papers/37873253PubMed
37603573NKG2D promotes CD8 T cell-mediated cytotoxicity and is associated with treatment failure in human cutaneous leishmaniasis.PLoS Negl Trop Dis2023https://conductscience.org/library/papers/37603573PubMed
36439094Granzyme B in circulating CD8+ T cells as a biomarker of immunotherapy effectiveness and disability in neuromyelitis optica spectrum disorders.Front Immunol2022https://conductscience.org/library/papers/36439094PubMed
35757700Remodeling of T Cell Dynamics During Long COVID Is Dependent on Severity of SARS-CoV-2 Infection.Front Immunol2022https://conductscience.org/library/papers/35757700PubMed
35456141Protection and Pathology in Leishmania braziliensis Infection.Pathogens2022https://conductscience.org/library/papers/35456141PubMed

See all 25 cited byDownload CSV of cited by

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
GZMB3002PubTator's text mininghttps://conductscience.org/library/genes/3002NCBI Gene
IFNG3458PubTator's text mininghttps://conductscience.org/library/genes/3458NCBI Gene
IL12B3593PubTator's text mininghttps://conductscience.org/library/genes/3593NCBI Gene
IL153600PubTator's text mininghttps://conductscience.org/library/genes/3600NCBI Gene
IL2RG3561PubTator's text mininghttps://conductscience.org/library/genes/3561NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32738245

GET https://conductscience.org/api/papers/v1/32738245/references?page=2